<DOC>
	<DOC>NCT01742208</DOC>
	<brief_summary>This Phase 2 study is intended to assess the pharmacodynamics (PD), pharmacokinetics (PK), safety and efficacy of LX4211 following daily oral administration for 29 days in patients with type 1 diabetes mellitus (T1DM).</brief_summary>
	<brief_title>Safety and Efficacy of LX4211 in Patients With Inadequately Controlled Type 1 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 1</mesh_term>
	<criteria>Adults ≥18 to ≤55 years of age Confirmed diagnosis of T1DM, diagnosed prior to age 40 years, and for at least 6 months prior to Screening Willing to refrain from using carbohydrate counting to adjust insulin during the study Willing and able to wear and operate a continuous glucose monitor Willing and able to selfassess bloodglucose Willing and able to provide written informed consent History of type 2 diabetes mellitus or diabetes resulting from acromegaly, Cushing's disease, chronic pancreatitis, or pancreatectomy Two or more severe episodes of hypoglycemia that required emergency treatment within 3 months prior to Screening Use of premixed insulin History of diabetic ketoacidosis within 1 year of screening Presence of active hepatic disease or clinically significant abnormal liver function tests History of chronic pancreatitis Subjects with a history of heart attack, severe/unstable angina, or coronary revascularization procedure History of clinically significant cardiac arrhythmias within 1 year prior to screening Subjects with congestive heart failure Subjects with uncontrolled Stage III hypertension History of human immunodeficiency virus (HIV) or hepatitis C History of illicit drug or alcohol abuse within 12 months prior to Screening Use of any investigational agent or device within 30 days prior to Screening or any therapeutic protein or antibody within 90 days prior to Screening Use of medication or herbal supplements taken for weight loss within 2 weeks of screening Chronic use of any antidiabetic therapy other than insulin within 2 months prior to Screening Use of systemic or inhaled corticosteroids within 2 weeks prior to Screening Subjects who have undergone major surgery within 6 months prior to Screening Inability or difficulty swallowing whole tablets or capsules Women who are pregnant or breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>